接受俯卧位通气的COVID-19相关ARDS患者呼吸亚型的识别与验证
该前瞻性队列纳入718例PCR确诊COVID-19、因中重度ARDS临床指征接受俯卧位通气的连续机械通气患者,按时间分割分为开发队列504例和验证队列214例。研究在第1次俯卧位期间纵向评估PaO2/FiO2、呼吸系统顺应性和通气比,用K-means联合轨迹聚类在开发队列无监督分类,再用随机森林模型在验证队列验证。结果识别出亚型A和亚型B两种呼吸亚型,亚型B俯卧位期间PaO2/FiO2反应更低、通气比更高、顺应性更低,女性比例更高(p<0.001)、肺疾病比例更高(p=0.005)、基线SAPS III(p=0.002)和SOFA(p<0.001)评分更高、体重指数更低(p=0.05)、IL-6水平更高(p=0.017)。亚型B与60天死亡风险升高独立相关(OR 1.89,95%CI 1.51-2.36),并与第28天无呼吸机天数更少(p<0.001)和住院时间更短(p<0.001)相关,亚型在验证队列中可重复。
要点
- 718例COVID-19 ARDS俯卧位通气患者中识别出亚型A和B两种呼吸亚型,并在214例验证队列中可重复。
- 亚型B在俯卧位期间PaO2/FiO2反应更低、通气比更高、呼吸系统顺应性更低。
- 亚型B与60天死亡风险升高独立相关:OR 1.89,95%CI 1.51-2.36。
- 亚型B女性比例更高(p<0.001)、肺疾病比例更高(p=0.005)、基线SAPS III(p=0.002)和SOFA(p<0.001)评分更高、体重指数更低(p=0.05)、IL-6更高(p=0.017)。
- 亚型B第28天无呼吸机天数更少(p<0.001)、住院时间更短(p<0.001)。
适用人群与场景
- PCR确诊COVID-19感染的连续机械通气患者,因中重度ARDS临床指征接受俯卧位通气。
研究设计与关键结果
- 前瞻性队列分析纳入718例,按时间分割分为开发队列504例和验证队列214例。
- 使用K-means联合轨迹聚类对开发队列无监督分类,随机森林模型在开发队列训练后用于验证队列验证亚型。
- 识别出亚型A和亚型B两种呼吸亚型;亚型B俯卧位期间PaO2/FiO2反应更低、通气比更高、顺应性更低。
- 亚型B女性比例更高(p<0.001)、肺疾病比例更高(p=0.005)、基线SAPS III更高(p=0.002)、SOFA更高(p<0.001)、体重指数更低(p=0.05)、IL-6水平更高(p=0.017)。
- 亚型B与60天死亡风险升高独立相关(OR 1.89,95%CI 1.51-2.36)。
- 亚型B与第28天无呼吸机天数更少相关(p<0.001),与住院时间更短相关(p<0.001)。
- 亚型在验证队列中可重复。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性;作者在结论中提出未来需开展研究探索这些新亚型用于指导COVID-19 ARDS靶向治疗策略的价值。
对床旁实践的改变
- 作者认为,基于关键呼吸参数识别的两种亚型可能有助于更好的患者分层、风险评估和治疗个体化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The heterogeneity of acute respiratory distress syndrome (ARDS) patients is a challenge for the development of effective treatments. This study aimed to identify and characterize novel respiratory subphenotypes of COVID-19 ARDS, with potential implications for targeted patient management.
METHODS: Consecutive ventilated patients with PCR-confirmed COVID-19 infection, in which prone positioning was clinically indicated for moderate or severe ARDS, were included in a prospective cohort. The patients were assigned to development or validation cohorts based on a temporal split. The PaO2/FiO2 ratio, respiratory compliance, and ventilatory ratio were assessed longitudinally throughout the first prone session. The subphenotypes were derived and validated using machine learning techniques. A K-means clustering implementation designed for joint trajectory analysis was utilized for the unsupervised classification of the development cohort. A random forest model was trained on the labeled development cohort and used to validate the subphenotypes in the validation cohort.
RESULTS: 718 patients were included in a prospective cohort analysis. Of those, 504 were assigned to the development cohort and 214 to the validation cohort. Two distinct subphenotypes, labeled A and B, were identified. Subphenotype B had a lower PaO2/FiO2 response during the prone session, higher ventilatory ratio, and lower compliance than subphenotype A. Subphenotype B had a higher proportion of females (p < 0.001) and lung disease (p = 0.005), higher baseline SAPS III (p = 0.002) and SOFA (p < 0.001) scores, and lower body mass index (p = 0.05). Subphenotype B had also higher levels of the pro-inflammatory biomarker IL-6 (p = 0.017). Subphenotype B was independently associated with an increased risk of 60-day mortality (OR 1.89, 95% CI 1.51-2.36). Additionally, Subphenotype B was associated with a lower number of ventilator-free days on day 28 (p < 0.001) and a lower hospital length of stay (p < 0.001). The subphenotypes were reproducible in the validation cohort.
CONCLUSION: Our study successfully identified and validated two distinct subphenotypes of COVID-19 ARDS based on key respiratory parameters. The findings suggest potential implications for better patient stratification, risk assessment, and treatment personalization. Future research is warranted to explore the utility of these novel subphenotypes for guiding targeted therapeutic strategies in COVID-19 ARDS.
参考来源
- da Cruz MR, Azambuja P, Torres KSC, et al. Identification and validation of respiratory subphenotypes in patients with COVID-19 acute respiratory distress syndrome undergoing prone position. Ann Intensive Care. 2024. PMID: 39612112. doi:10.1186/s13613-024-01414-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。